DVAX - Dynavax Technologies Corporation (NASDAQ Stock)

[Aufan 1983]

This made a big move this morning on the news below. I got in @ .75 and then left the office and came back to see it was still moving.

52 week low = .15 52 week high = 6.55

Dynavax in deal with GlaxoSmithKline worth up to $800MSan Francisco Business Times
Print Email Reprints RSS Feeds Add to Del.icio.us Digg This CommentsRelated News
Dynavax cuts loss through collaboration
Exelixis lands $240M deal with Bristol-Myers Squibb
GlaxoSmithKline, Dynavax agree to $800M drug development deal

Synta earns $15M milestone payment
GlaxoSmithKline has signed a drug development deal with Dynavax Technologies Corp. that could be worth as much as $800 million.

GlaxoSmithKline (NYSE: GSK) will pay $10 million upfront to Dynavax Technologies Corp. (NASDAQ: DVAX) of Berkeley.

In addition, Glaxo will work with Dynavax to develop drugs in four separate programs. Dynavax could receive as much as $200 million per program in milestone payments during development and commercialization, and company would receive royalties on sales of any drugs.

In return, GSK gets the rights to license the Dynavax drugs from the development programs, which are targeting autoimmune and inflammatory diseases such as lupus, psoriasis and rheumatoid arthritis.

“We are committed to using our expertise, in collaboration with Dynavax, to research and develop new therapeutics that can improve the lives of patients with conditions like systemic lupus erythematosus, psoriasis and rheumatoid arthritis,” Jose Carlos Gutierrez-Ramos, head of GSK’s Immuno-Inflammation Centre of Excellence for Drug Discovery, said in a written statement.

GSK has said repeatedly in recent months that it wants to look outside the company for good science as its own pipeline of experimental drugs slows. The company has slowed its stock buyback plan dramatically in order to make smart deals at good prices, CEO Andrew Witty says.

Glaxo’s recently announced deals include the $57 million purchase of Genelabs Technologies, a drug development deal for Alzheimer’s treatments with Austrian company Affiris GmbH that could total $550 million, and the $170 million purchase of the dry-mouth treatment Biotene to strengthen GSK’s consumer health care portfolio.

GlaxoSmithKline, based in London, has more than 5,000 split between two Triangle employees – the U.S. headquarters in Research Triangle Park

[thegreatgate]

DVAX back up into the high $1.50's. Another stock I added to my streamer this morning off of google finance was NVD. NVD did not budge for about 4 hours straight, it sat at .19/.20 cents. All of a sudden in the last hour and a half it got all the way up to .37??

[paperchase]

Dynavax Presents Additional Phase 3 Data for HEPLISAVTM Hepatitis B Vaccine at DDW Medical Conference
9:00a ET June 3, 2009 (Business Wire)
Dynavax Technologies Corporation (Nasdaq:DVAX) today presented additional Phase 3 clinical data for HEPLISAV(TM) hepatitis B vaccine in a poster session at the Digestive Disease Week (DDW) medical conference in Chicago. In addition to meeting its primary endpoint in this Phase 3 trial as previously reported, HEPLISAV provided more rapid and increased seroprotection against hepatitis B viral infection and with fewer doses than the licensed vaccine. The data show the differences to be particularly significant in the subset of subjects over 40 years of age who are usually less likely to respond to immunization.

"Vaccination is critical for the prevention of hepatitis B viral infection and its spread, but the lengthy dosing regimen of current vaccines leaves many unprotected," commented Scott A. Halperin, M.D., Director Clinical Trials Research Center, Dalhousie University, IWK Heath Centre of Halifax, Nova Scotia and Lead Investigator in the Phase 3 trial. "The Phase 3 data demonstrate HEPLISAV's superior immunogenicity and similar safety profile versus the licensed vaccine, particularly for adults over 40 who are more difficult to protect against this preventable viral infection."

This Phase 3 trial referred to as PHAST (Phase 3 HeplisAv Short-regimen Trial) evaluated more than 2,400 adults. The seroprotection rate at the primary endpoint was 95% in subjects receiving 2 doses of HEPLISAV at 0 and 1 month, compared to 81% in subjects receiving 3 doses of licensed vaccine Engerix-B(R) at 0, 1, and 6 months.

In a subanalysis of subjects over 40 years of age, at each time point during the trial there was a statistically significant (p < 0.0001) difference in the seroprotection rate for subjects receiving HEPLISAV or Engerix-B.

Ages 40-55 Dosing Regimen Seroprotection Rate (1) Treatment Group at Month 1 2 3 6 7 HEPLISAV 2 doses (0, 1 month) 18% 84% 92%(2) 97% 97% Engerix-B 3 doses (0, 1, 6 months) 3% 21% 17% 27% 75%(2)

A copy of the poster is available at Dynavax Technologies Corporation - News & Events (http://investors.dynavax.com/newsevents.cfm). Dynavax's abstract #587659 is titled "A Phase 3 Safety and Efficacy Study to Compare Immune Responses following Either Two Doses of Hepatitis B Surface Antigen Combined with Immunostimulatory Phosphorothioate Oligonucleotide (HBsAg-ISS) or Three Doses of Conventional Hepatitis B Vaccine."

As previously reported, safety results from this trial demonstrated the safety profile of HEPLISAV and Engerix-B appeared similar. Subjects were randomized 3 to 1 to receive HEPLISAV or Engerix-B and one case of vasculitis was reported in each of the treatment groups. Following the report of the severe adverse event of Wegener's granulomatosis, an uncommon form of vasculitis, HEPLISAV was placed and remains on clinical hold by the U.S. Food and Drug Administration (FDA). Dynavax is in active discussions with regulatory agencies to resolve the FDA's clinical hold on HEPLISAV and identify an appropriate path for its further development and approval in the United States, Europe, and the rest of the world.

About HEPLISAV

HEPLISAV is a Phase 3 hepatitis B vaccine aimed at unmet medical needs in the vaccination of adults and end-stage renal disease patients by providing rapid and increased protection with fewer doses. HEPLISAV combines a proprietary immunostimulatory sequence (ISS), which targets Toll-like Receptor 9, with hepatitis B surface antigen (HBsAg).

[Theboundbook]

Hope you bought this one also!!! Another 30+% today....

[thegreatgate]

$2.57 (+46.86% at last trade)

[lovemoney]

DVAX looks like it could start moving up.

DVAX - SharpCharts Workbench : StockCharts.com (http://stockcharts.com/h-sc/ui?s=DVAX&p=D&b=4&g=0&id=p05410425696)

[lovemoney]

making a nice move today

[affreillc]

Dynavax technologies was established over 14 years ago and has been a pioneer in the development of toll-like receptor (TLR) based therapy. By focusing on hepatitis B, Dynavax has made significant progress in the development of HEPLISAV hepatitis B vaccine to population which is refractory to current vaccine therapy. Dynavax is attempting to extend its TLR based research and development to fields of asthma, autoimmune diseases, etc. The big question is who is the competition and did the FDA previously approve TLR based therapy.

Biotech Explorers, Inc. | Home (http://www.biotechexplorers.com)

[BadThad]

Please take a minute to read the http://www.stockmarketcats.com/f5/posting-rules-guidelines-1696.html.

Thanks

[greencat]

DVAX has a trendline break and possible cup pattern in progress.

DVAX Chart
http://www.profitspi.com/stock-chart-str.aspx?id=DVAX&ca=1071167772